DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Duration and Severity of Symptoms and Levels of Plasma Interleukin-1 Receptor Antagonist, Soluble Tumor Necrosis Factor Receptor, and Adhesion Molecules in Patients with Common Cold Treated with Zinc Acetate.

Author(s): Prasad AS, Beck FW, Bao B, Snell D, Fitzgerald JT

Affiliation(s): 1Wayne State University School of Medicine, Detroit, and 2University of Michigan Medical School, Ann Arbor.

Publication date & source: 2008-02-15, J Infect Dis., [Epub ahead of print]

Background. @nbsp; Zinc lozenges have been used for treatment of the common cold; however, the results remain controversial. Methods. @nbsp; Fifty ambulatory volunteers were recruited within 24 h of developing symptoms of the common cold for a randomized, double-blind, placebo-controlled trial of zinc. Participants took 1 lozenge containing 13.3 mg of zinc (as zinc acetate) or placebo every 2-3 h while awake. The subjective scores for common cold symptoms were recorded daily. Plasma zinc, soluble interleukin (IL)-1 receptor antagonist (sIL-1ra), soluble tumor necrosis factor receptor 1, soluble vascular endothelial cell adhesion molecule, and soluble intercellular adhesion molecule (sICAM)-1 were assayed on days 1 and 5. Results. @nbsp; Compared with the placebo group, the zinc group had a shorter mean overall duration of cold (4.0 vs. 7.1 days; [Formula: see text]) and shorter durations of cough (2.1 vs. 5.0 days; [Formula: see text]) and nasal discharge (3.0 vs. 4.5 days, [Formula: see text]). Blinding of subjects was adequate, and adverse effects were comparable in the 2 groups. Symptom severity scores were decreased significantly in the zinc group. Mean changes in plasma levels of zinc, sIL-1ra, and ICAM-1 differed significantly between groups. Conclusion. @nbsp; Administration of zinc lozenges was associated with reduced duration and severity of cold symptoms. We related the improvement in cold symptoms to the antioxidant and anti-inflammatory properties of zinc.

Page last updated: 2008-03-26

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017